Phase II randomized, open-label study of YM155 (sepantronium bromide) plus docetaxel versus docetaxel alone as first-line treatment for HER2 negative metastatic breast cancer.
Michael R. Clemens
Research Funding - Astellas Pharma
Anne Therese Keating
Employment or Leadership Position - Astellas Pharma
Oleg Gladkov
No relevant relationships to disclose
Fei Jie
Employment or Leadership Position - Astellas Pharma
Joyce Steinberg
Employment or Leadership Position - Astellas Pharma
Elaina M. Gartner
No relevant relationships to disclose
John Crown
Consultant or Advisory Role - Astellas Pharma
Honoraria - Sanofi
Vladimir Ivanovich Vladimirov
No relevant relationships to disclose